School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Cell Infect Microbiol. 2022 Aug 25;12:854885. doi: 10.3389/fcimb.2022.854885. eCollection 2022.
With socioeconomic advances and improved living standards, metabolic syndrome has increasingly come into the attention. In recent decades, a growing number of studies have shown that the gut microbiome and its metabolites are closely related to the occurrence and development of many metabolic diseases, and play an important role that cannot be ignored, for instance, obesity, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cardiovascular disease and others. The correlation between gut microbiota and metabolic disorder has been widely recognized. Metabolic disorder could cause imbalance in gut microbiota, and disturbance of gut microbiota could aggravate metabolic disorder as well. Berberine (BBR), as a natural ingredient, plays an important role in the treatment of metabolic disorder. Studies have shown that BBR can alleviate the pathological conditions of metabolic disorders, and the mechanism is related to the regulation of gut microbiota: gut microbiota could regulate the absorption and utilization of berberine in the body; meanwhile, the structure and function of gut microbiota also changed after intervention by berberine. Therefore, we summarize relevant mechanism research, including the expressions of nitroreductases-producing bacteria to promote the absorption and utilization of berberine, strengthening intestinal barrier function, ameliorating inflammation regulating bile acid signal pathway and axis of bacteria-gut-brain. The aim of our study is to clarify the therapeutic characteristics of berberine further and provide the theoretical basis for the regulation of metabolic disorder from the perspective of gut microbiota.
随着社会经济的进步和生活水平的提高，代谢综合征越来越受到关注。近几十年来，越来越多的研究表明，肠道微生物群及其代谢物与许多代谢性疾病的发生和发展密切相关，其作用不可忽视，例如肥胖、2 型糖尿病（T2DM）、非酒精性脂肪性肝病（NAFLD）、心血管疾病等。肠道微生物群与代谢紊乱之间的相关性已得到广泛认可。代谢紊乱可导致肠道微生物群失衡，而肠道微生物群的紊乱也可加重代谢紊乱。小檗碱（BBR）作为一种天然成分，在治疗代谢紊乱方面发挥着重要作用。研究表明，BBR 可缓解代谢紊乱的病理状况，其机制与调节肠道微生物群有关：肠道微生物群可调节体内小檗碱的吸收和利用；同时，小檗碱干预后肠道微生物群的结构和功能也发生了变化。因此，我们总结了相关的机制研究，包括产硝基还原酶细菌促进小檗碱的吸收和利用、增强肠道屏障功能、改善炎症、调节胆汁酸信号通路和细菌-肠道-大脑轴。我们的研究旨在进一步阐明小檗碱的治疗特性，并从肠道微生物群的角度为代谢紊乱的调节提供理论依据。
